Interestingly, this classic and widespread toxin-based animal model of PD has been successfully used in preclinical studies of antiparkinsonian drugs, including A2AR antagonists (Hodgson et al., 2009; Pinna, 2009). Here, ADORA2A is linked to Parkinson disease.